femoston 1 mg / 10 mg
viatris healthcare ltd. - Østradiolhemihydrat / dydrogesteron - tablett, filmdrasjert - 1 mg / 10 mg
femostonconti 1 mg / 5 mg
viatris healthcare ltd. - Østradiolhemihydrat / dydrogesteron - tablett, filmdrasjert - 1 mg / 5 mg
femostonconti 0.5 mg / 2.5 mg
viatris healthcare ltd. - Østradiolhemihydrat / dydrogesteron - tablett, filmdrasjert - 0.5 mg / 2.5 mg
octreoanne 30 mg
teva b.v. - oktreotidacetat - pulver og væske til depotinjeksjonsvæske, suspensjon - 30 mg
octreoanne 10 mg
teva b.v. - oktreotidacetat - pulver og væske til depotinjeksjonsvæske, suspensjon - 10 mg
octreoanne 20 mg
teva b.v. - oktreotidacetat - pulver og væske til depotinjeksjonsvæske, suspensjon - 20 mg
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystisk fibrose - andre åndedrettsprodukter - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
noresmea 1 mg / 0.5 mg
sandoz - københavn - Østradiolhemihydrat / noretisteronacetat - tablett, filmdrasjert - 1 mg / 0.5 mg
ronapreve
roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - immune sera og immunglobuliner, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. se avsnitt 4. 4 og 5.
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.